JF
ZNTL icon

Jump Financial’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Jump Financial’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.4K Buy
+17,809
New +$71.1K ﹤0.01% 1912
2025
Q3 		– Sell
-11,692
Closed -$13.6K – 2302
2025
Q2 		$13.6K Buy
+11,692
New +$15.4K ﹤0.01% 1744
2024
Q4 		– Sell
-33,557
Closed -$123K – 2074
2024
Q3 		$123K Buy
+33,557
New +$122K ﹤0.01% 1515
2024
Q2 		– Sell
-118,648
Closed -$1.87M – 2347
2024
Q1 		$1.87M Buy
+118,648
New +$1.63M 0.05% 484
2023
Q3 		– Sell
-31,570
Closed -$891K – 2321
2023
Q2 		$891K Sell
31,570
-14,125
-31% -$339K 0.03% 739
2023
Q1 		$786K Buy
+45,695
New +$925K 0.03% 705
2021
Q1 		– Sell
-8,600
Closed -$447K – 1348
2020
Q4 		$447K Buy
+8,600
New +$388K 0.08% 417

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Jump Financial's ZNTL Position: Q2 2026 in Review

Jump Financial opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 17,809 shares worth $86.4K. The stake represents ﹤0.01% of the portfolio and ranks #1912 among its holdings. This is a return to the name: Jump Financial previously reported a position in ZNTL as recently as Q2 2025.

Jump Financial first reported a position in ZNTL in Q4 2020 and has held it in 7 quarters since. The position peaked at $1.87M in Q1 2024. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Jump Financial held 17,809 shares of Zentalis Pharmaceuticals worth $86.4K as of Q2 2026.
  • Zentalis Pharmaceuticals was a new Jump Financial position in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Jump Financial's portfolio in Q2 2026, its #1912 holding.
  • Jump Financial first reported a position in Zentalis Pharmaceuticals in Q4 2020 and has held it in 7 quarters since.
  • Jump Financial's Zentalis Pharmaceuticals position peaked at $1.87M in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.